Ospedale Pediatrico Bambino Gesu
Ospedale Pediatrico Bambino Gesu
Rome, Italy8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Cholangitis, Sclerosing, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Abnormalities, Digestive System Diseases, Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, bile duct disorder, biliary atresia, biliary tract disorder, cholangitis, skin disorder | Active, not recruiting | Phase 3 | 2026-10-06 | NCT06553768 | |
| Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome | Abnormalities, Multiple, Alagille syndrome, Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, bile duct disorder, biliary tract disorder, cardiovascular disorder, cholestasis, congenital heart disease, hereditary disease, intrahepatic cholestasis, liver disorder | Active, not recruiting | Phase 3 | 2026-10-02 | NCT05035030 | |
| Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies | Hemic and Lymphatic Diseases, Neoplasms by Site, autoimmune disease, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, neoplasm | Enrolling by invitation | Not stated | 2026-09-21 | NCT05041309 | |
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-18 | NCT03435796 | |
| A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne muscular dystrophy, Muscular Disorders, Atrophic, X-linked disease, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Phase 1 / Phase 2 | 2026-08-13 | NCT07038824 | |
| A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne muscular dystrophy, Muscular Disorders, Atrophic, X-linked disease, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Recruiting | Phase 1 / Phase 2 | 2026-08-13 | NCT07037862 | |
| Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne muscular dystrophy, Muscular Disorders, Atrophic, X-linked disease, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease | Not yet recruiting | Phase 2 | 2026-07-02 | NCT07682129 | |
| International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Not yet recruiting | Phase 3 | 2026-03-17 | NCT07476729 |